menu
    • menu
    [{"orgOrder":0,"company":"New American Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Metoprolol Succinate","moa":"Adrenergic beta-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"New American Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"New American Therapeutics \/ Melinta","highestDevelopmentStatusID":"12","companyTruncated":"New American Therapeutics \/ Melinta"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Metoprolol Succinate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Biocon Biologics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Biocon Biologics \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Metoprolol Succinate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Metoprolol Succinate

    Menu

    Metoprolol Succinate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Granules India Limited

                            India
                            CPhI India 2024
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

                            Lead Product(s) : Metoprolol Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Granules India Limited Received ANDA Approval for Metoprolol Succinate ER Tablets

                            Details : Generic version of Metoprolol Succinate ER Tablets have been approved, these are catecholamines inhibitor indicated for the treatment of hypertension in order to lower blood pressure.

                            Brand Name : Toprol-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 13, 2023

                            Lead Product(s) : Metoprolol Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Granules India

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biocon Biologics

                            India arrow
                            2024 ACI Convention
                            Not Confirmed

                            Biocon Biologics

                            India arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metoprolol Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Eris Pharmaceuticals

                            Deal Size : $150.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln

                            Details : The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.

                            Brand Name : ACTIBLOK IPR 25

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 13, 2024

                            Lead Product(s) : Metoprolol Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Eris Pharmaceuticals

                            Deal Size : $150.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            New American Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            New American Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metoprolol Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Melinta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) From New American Therapeutics

                            Details : TOPROL-XL®, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic, heart failure of speci...

                            Brand Name : Toprol-XL

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 06, 2022

                            Lead Product(s) : Metoprolol Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Melinta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth